Fed. Circ. OKs Hikma Gout Drug Sales In Takeda IP Case
Law360, New York (May 6, 2015, 7:11 PM EDT) -- The Federal Circuit on Wednesday released an opinion affirming a lower court's decision not to bar sales of Hikma Pharmaceuticals PLC's gout drug Mitigare, finding that Takeda Pharmaceuticals USA Inc. had failed to prove Hikma induced infringement of its patents on a gout treatment.
In a 2-1 decision, the appeals court affirmed a Delaware federal judge's ruling denying Takeda's motion for a preliminary injunction on Hikma, holding there is not sufficient evidence that instructions on the label for Mitigare would induce doctors to infringe patents owned by Takeda for a similar gout drug called Colcrys.
"We conclude that the district court...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!